Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Flubendazole→

Flubendazole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
31430-15-6
Molecular formula
C16H12FN3O3
Molecular weight
313.28 g/mol
Drug class
Benzimidazole anthelminticparasite microtubule inhibitor
Mechanism of action
Binds parasite beta-tubulin and inhibits microtubule polymerisation, disrupting glucose uptake and intracellular transport and leading to energy depletion and parasite death.
Indications / reported uses
  • Treatment of intestinal helminth infections in countries where flubendazole products are authorised, including selected nematode infections; indications, age criteria and formulation are jurisdiction-specific

Sources: WHO — Soil-transmitted helminthiases treatment guidance · NLM MeSH — Flubendazole · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Flubendazole Environmental Risk Assessment (ERA) (the Flubendazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.